BR9912672A - Prevenção de produção de muco no trato respiratório por administração de antagonistas de egf-r - Google Patents

Prevenção de produção de muco no trato respiratório por administração de antagonistas de egf-r

Info

Publication number
BR9912672A
BR9912672A BR9912672-9A BR9912672A BR9912672A BR 9912672 A BR9912672 A BR 9912672A BR 9912672 A BR9912672 A BR 9912672A BR 9912672 A BR9912672 A BR 9912672A
Authority
BR
Brazil
Prior art keywords
egf
respiratory tract
administration
antagonists
prevention
Prior art date
Application number
BR9912672-9A
Other languages
English (en)
Inventor
Jay A Nadel
Kiyoshi Takeyama
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of BR9912672A publication Critical patent/BR9912672A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Environmental Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"PREVENçãO DA PRODUçãO DE MUCO DO TRATO RESPIRATóRIO POR ADMINISTRAçãO DE ANTAGONISTAS DE EGF-R". A hipersecreção de muco nos pulmões é inibida por administração de um antagonista do receptor do fator de crescimento epidérmico ( EGF-R ). O antagonista de EGF-R pode estar na forma de uma pequena molécula orgânica, um anticorpo, ou parte de um anticorpo, que se liga ao receptor de EGF e o bloqueia. O antagonista de EGF-R é de preferência administrado por injeção, numa quantidade suficiente para inibir a formação de células caliciformes no trato respiratório pulmonar. A desgranulação das células caliciformes que resulta na produção de muco do trato respiratório é por isso impedida. São também providenciados testes para seleção de agentes candidatos que inibem a proliferação celular caliciforme.
BR9912672-9A 1998-08-18 1999-08-17 Prevenção de produção de muco no trato respiratório por administração de antagonistas de egf-r BR9912672A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9702398P 1998-08-18 1998-08-18
PCT/US1999/018696 WO2000010588A2 (en) 1998-08-18 1999-08-17 Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs

Publications (1)

Publication Number Publication Date
BR9912672A true BR9912672A (pt) 2002-06-11

Family

ID=22260380

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9912672-9A BR9912672A (pt) 1998-08-18 1999-08-17 Prevenção de produção de muco no trato respiratório por administração de antagonistas de egf-r

Country Status (35)

Country Link
US (6) US6270747B1 (pt)
EP (2) EP1119349B1 (pt)
JP (2) JP2002539072A (pt)
KR (1) KR100609646B1 (pt)
CN (1) CN1184961C (pt)
AR (1) AR020220A1 (pt)
AT (1) ATE399541T1 (pt)
AU (1) AU760766B2 (pt)
BR (1) BR9912672A (pt)
CA (1) CA2337422C (pt)
CO (1) CO5130028A1 (pt)
CY (1) CY1110370T1 (pt)
CZ (1) CZ2001584A3 (pt)
DE (1) DE69939022D1 (pt)
DK (1) DK1119349T3 (pt)
EA (1) EA004316B1 (pt)
EE (1) EE200100097A (pt)
ES (1) ES2310047T3 (pt)
HR (1) HRP20010119B1 (pt)
HU (1) HUP0103894A3 (pt)
ID (1) ID27345A (pt)
IL (2) IL140855A0 (pt)
MY (1) MY126490A (pt)
NO (1) NO327000B1 (pt)
NZ (1) NZ509271A (pt)
PH (2) PH12010000216A1 (pt)
PL (1) PL200940B1 (pt)
PT (1) PT1119349E (pt)
RS (1) RS50273B (pt)
SI (1) SI1119349T1 (pt)
SK (1) SK287805B6 (pt)
TR (1) TR200100560T2 (pt)
TW (1) TWI250019B (pt)
UA (1) UA73722C2 (pt)
WO (1) WO2000010588A2 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1119349B1 (en) 1998-08-18 2008-07-02 The Regents Of The University Of California Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs
US7354894B2 (en) 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US6846799B1 (en) 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US20030149113A1 (en) * 2001-10-12 2003-08-07 Caplan Michael J. Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
US20030236300A1 (en) * 1999-10-27 2003-12-25 Yale University Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
WO2002094318A1 (en) * 2001-05-18 2002-11-28 University Of Southern California Vector for targeted delivery to cells
US6818446B2 (en) 2001-11-21 2004-11-16 The Regents Of The University Of California Compositions and methods for the analysis of mucin gene expression and identification of drugs having the ability to inhibit mucin gene expression
DE10204462A1 (de) * 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
US6924285B2 (en) * 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
JP2005529123A (ja) * 2002-04-24 2005-09-29 リサーチ　ディベロップメント　ファンデーション 核転写調節因子ＮＦ−κＢ抑制剤と抗腫瘍薬の相乗効果
AU2003253681B2 (en) * 2002-06-24 2008-05-01 Research Development Foundation Treatment of human multiple myeloma by Curcumin
US20060241130A1 (en) * 2003-01-31 2006-10-26 Ehud Keinan Anti-inflammatory compositions and uses thereof
US7195899B1 (en) * 2003-03-14 2007-03-27 Florida State University Research Foundation, Inc. Cell-based biosensor for harmful airborne agents
WO2005020958A2 (en) * 2003-08-26 2005-03-10 Research Development Foundation Aerosol delivery of curcumin
EP1694335A4 (en) 2003-08-26 2008-12-31 Res Dev Foundation OSTEOCLASTOGENESIS INHIBITORS AND USES THEREOF
US11324698B2 (en) 2003-08-28 2022-05-10 Vgsk Technologies, Inc. Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
US20060115523A1 (en) * 2004-12-01 2006-06-01 Konduri Kameswari S Sterically stabilized liposome and triamcinolone composition for treating the respiratory tract of a mammal
US8846079B1 (en) 2004-12-01 2014-09-30 Vgsk Technologies, Inc. Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
US20050096332A1 (en) * 2003-10-30 2005-05-05 Boehringer Ingelheim International Gmbh Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
PT1687338E (pt) 2003-11-07 2011-01-20 Ablynx Nv Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações
US7968575B2 (en) * 2004-05-05 2011-06-28 Renopharm Ltd. Nitric oxide donors and uses thereof
US8134010B2 (en) * 2004-05-05 2012-03-13 Renopharm Ltd. Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof
EP1753734A1 (en) * 2004-05-05 2007-02-21 Renopharm Ltd. Nitric oxide donors and uses thereof
US7498445B2 (en) * 2004-05-05 2009-03-03 Renopharm Ltd. Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof
US6998028B1 (en) * 2004-09-24 2006-02-14 Superpower, Inc. Methods for forming superconducting conductors
US7915223B2 (en) * 2004-09-27 2011-03-29 Technion Research & Development Foundation Ltd. Antimicrobial agents
EP1793837A2 (en) * 2004-09-27 2007-06-13 Technion Research & Development Foundation Limited Fatty acid modified polylysines as antimicrobial agents
TW200616536A (en) * 2004-09-28 2006-06-01 Dainippon Ink & Chemicals Animal for drug efficacy evaluation, method for developing chronic obstructive pulmonary disease in animal for drug efficacy evaluation, and method for evaluation drug efficacy using the animal
JP4690158B2 (ja) * 2004-09-28 2011-06-01 スギ生物科学研究所株式会社 薬効評価用動物、薬効評価用動物の慢性閉塞性肺疾患発症方法及びその動物を用いた薬効評価方法
JP2009511586A (ja) * 2005-10-11 2009-03-19 ワシントン・ユニバーシティ 気道分泌過多を治療するための組成物および方法
EP1921070A1 (de) * 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
JP5377332B2 (ja) * 2007-02-06 2013-12-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二環式へテロ環、それらの化合物を含む薬剤、その使用及びその製法
WO2008124496A1 (en) * 2007-04-03 2008-10-16 Parion Sciences, Inc. Method of treating acid-sensing ion channel mediated pain, cough, and central nervous system disorders
WO2008132737A1 (en) * 2007-04-30 2008-11-06 Technion Research & Development Foundation Ltd. Novel antimicrobial agents
WO2008132738A2 (en) * 2007-04-30 2008-11-06 Technion Research & Development Foundation Ltd. Anticancerous polymeric agents
WO2009098061A1 (de) 2008-02-07 2009-08-13 Boehringer Ingelheim International Gmbh Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
EP2313397B1 (de) * 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
US8112365B2 (en) * 2008-12-19 2012-02-07 Foster Scott C System and method for online employment recruiting and evaluation
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
US9066974B1 (en) 2010-11-13 2015-06-30 Sirbal Ltd. Molecular and herbal combinations for treating psoriasis
US9095606B1 (en) 2010-11-13 2015-08-04 Sirbal Ltd. Molecular and herbal combinations for treating psoriasis
US8734859B1 (en) 2010-11-13 2014-05-27 Sirbal Ltd. Molecular combinations for cancer or other disease treatment
US8541382B2 (en) 2010-11-13 2013-09-24 Sirbal Ltd. Cardiac glycoside analogs in combination with emodin for cancer therapy
DK2665741T3 (en) * 2011-01-10 2019-04-29 Invion Inc APPLICATION OF BETA-ADRENERGE INVERSE AGONISTS FOR SMOKE CLEANING
US20170049687A1 (en) 2015-07-29 2017-02-23 Sirbal Ltd. Herbal Combinations For Treating Scalp Conditions
JP6618360B2 (ja) 2012-08-03 2019-12-11 セダーズ−シナイ メディカル センター 薬物送達タンパク質の輸送向上変異体の単離
CA3280124A1 (en) 2013-07-31 2025-10-31 Avalyn Pharma Inc. Aerosol imatinib compounds and uses thereof
WO2015082950A1 (en) 2013-12-02 2015-06-11 Sirbal Ltd. Herbal combinations for treatment of a skin condition
CN108289845A (zh) 2015-09-14 2018-07-17 维吉思康科技公司 皮下、舌下和口服治疗用空间稳定载体、用于治疗哺乳动物的组合物和方法
WO2022187563A1 (en) * 2021-03-03 2022-09-09 Georgia Tech Research Corporation Cell culture growth apparatus and method of underside attachment to a surface using cell seeding
AU2022270670A1 (en) 2021-05-05 2023-11-30 Nejat Duzgunes Liposome-encapsulated corticosteriods inhibit sars-cov-2 replication and reduces lung inflammation

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2932481A (en) * 1954-06-15 1960-04-12 Breer Bipod camera support
GB1242211A (en) * 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
FR2502627A1 (fr) * 1981-02-02 1982-10-01 Refarmed Sa Derives thioliques de l'erythromycine a activite therapeutique, procede de preparation et produits pharmaceutiques dans lesquels ils apparaissent
IT1173549B (it) * 1984-04-02 1987-06-24 Corvi Camillo Spa Estere dell'acido teofillin-7-acetico con il d,l-trans-sobrerolo avente attivita' mucosecretolitica-fluidificante e antibroncospastica, procedimento per la sua preparazione e sue composizioni farmaceutiche
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4904786A (en) * 1986-01-27 1990-02-27 American Home Products Corporation Quinoline compounds as antiallergic and antiinflammatory agents
US5089516A (en) * 1987-03-11 1992-02-18 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha 1-phenyl-3,5-pyrazolidinedione hydroxystyrene compounds which have tyrosine kinase inhibiting activity
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
AU4203789A (en) * 1988-09-28 1990-04-18 Upjohn Company, The 1,4-dihydrothionapthoquinone and heterocyclic congeners which inhibit lipoxygenase enzymes
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB8904009D0 (en) 1989-02-22 1989-04-05 Celltech Ltd Vector
US5362755A (en) * 1990-01-05 1994-11-08 Sepracor, Inc. Method for treating asthma using optically pure (R)-albuterol
US5302606A (en) * 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
US5165424A (en) 1990-08-09 1992-11-24 Silverman Harvey N Method and system for whitening teeth
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
AU658396B2 (en) * 1991-03-06 1995-04-13 Merck Patent Gesellschaft Mit Beschrankter Haftung Humanized and chimeric monoclonal antibodies
US5116616A (en) * 1991-04-29 1992-05-26 Bio-Technology General Corp. Use of intratracheal administration of SOD to protect humans from lung injury due to hyperoxia and hyperventilation
DE4117078A1 (de) 1991-05-25 1992-11-26 Boehringer Ingelheim Kg Verfahren zur herstellung therapeutisch anwendbarer aerosole
ES2141108T3 (es) 1991-07-02 2000-03-16 Inhale Inc Metodo y dispositivo para proporcionar medicamentos en aerosol.
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
DE4310051A1 (de) 1992-04-11 1993-10-14 Byk Gulden Lomberg Chem Fab Weitere Verwendung substituierter Pyridazine
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
EP0659046A1 (en) * 1992-09-11 1995-06-28 The Regents of The University of Michigan Non-human animal with xenograft of on airway populated by human cells
IL108367A0 (en) * 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
US5994341A (en) * 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
WO1995006764A2 (en) 1993-09-03 1995-03-09 Vpi Holdings Ltd. Oligonucleotides with rna cleavage activity
DK0719412T3 (da) * 1993-09-13 1999-07-19 Merck Frosst Canada Inc Fremgangsmåde til måling af metaplastiske ændringer i slimsecernerende epithelceller
CA2261433A1 (en) * 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
AU706417B2 (en) 1994-02-23 1998-06-17 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting the expression of disease related genes
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
US20030114379A1 (en) * 1994-03-08 2003-06-19 Human Genome Sciences, Inc. Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (MPIF-1)
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
ATE446955T1 (de) 1995-03-30 2009-11-15 Pfizer Prod Inc Chinazolinone derivate
EP0824525B1 (en) 1995-04-27 2001-06-13 AstraZeneca AB Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US5760041A (en) * 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
CN100503580C (zh) 1996-04-12 2009-06-24 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂
US5990097A (en) * 1996-07-29 1999-11-23 Cavalier Pharmaceuticals Methods of treating asthma with o-desulfated heparin
SE9603725D0 (sv) 1996-10-11 1996-10-11 Astra Ab New teatment
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
US6251912B1 (en) * 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
JP2001526230A (ja) 1997-12-19 2001-12-18 スミスクライン・ビーチャム・コーポレイション ヘテロアリール置換イミダゾール化合物、その医薬組成物および使用
DE69940808D1 (de) * 1998-03-04 2009-06-10 Bristol Myers Squibb Co Heterocyclen substituierte imidazopyrazine als protein- tyrosin-kinase-inhibitoren
US5968748A (en) * 1998-03-26 1999-10-19 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human HER-2 expression
EP1119349B1 (en) 1998-08-18 2008-07-02 The Regents Of The University Of California Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
TR200102505T2 (tr) 1999-02-27 2003-01-21 Boehringer Ingelheim Pharma Kg 4-amino-kinazolin ve kinolin türevleri.
WO2001029025A2 (en) * 1999-10-19 2001-04-26 Merck & Co., Inc. Tyrosine kinase inhibitors
US6627634B2 (en) 2000-04-08 2003-09-30 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
DE50111799D1 (de) 2000-04-08 2007-02-15 Boehringer Ingelheim Pharma Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
NO327000B1 (no) 2009-03-30
PH12010000215A1 (en) 2015-07-27
US6551989B2 (en) 2003-04-22
EP1119349A2 (en) 2001-08-01
CY1110370T1 (el) 2015-04-29
NO20010749D0 (no) 2001-02-14
WO2000010588A9 (en) 2000-08-10
RS50273B (sr) 2009-07-15
TR200100560T2 (tr) 2002-05-21
EA004316B1 (ru) 2004-02-26
EP1119349B1 (en) 2008-07-02
TWI250019B (en) 2006-03-01
KR100609646B1 (ko) 2006-08-04
US20080175797A1 (en) 2008-07-24
ID27345A (id) 2001-04-05
US8048844B1 (en) 2011-11-01
HK1036219A1 (en) 2001-12-28
CN1184961C (zh) 2005-01-19
DE69939022D1 (de) 2008-08-14
YU13201A (sh) 2005-07-19
NZ509271A (en) 2003-10-31
NO20010749L (no) 2001-04-17
SK2162001A3 (en) 2002-08-06
PL351765A1 (en) 2003-06-16
HRP20010119B1 (hr) 2008-05-31
WO2000010588A2 (en) 2000-03-02
ATE399541T1 (de) 2008-07-15
JP2009221212A (ja) 2009-10-01
US7358222B2 (en) 2008-04-15
IL140855A0 (en) 2002-02-10
KR20010085412A (ko) 2001-09-07
AU760766B2 (en) 2003-05-22
SK287805B6 (sk) 2011-10-04
HUP0103894A2 (hu) 2002-04-29
US6270747B1 (en) 2001-08-07
HRP20010119A2 (en) 2002-02-28
US20010036919A1 (en) 2001-11-01
EA200100136A1 (ru) 2001-10-22
IL140855A (en) 2011-02-28
CA2337422C (en) 2010-11-02
EE200100097A (et) 2002-06-17
US20030148990A1 (en) 2003-08-07
PL200940B1 (pl) 2009-02-27
US20010041178A1 (en) 2001-11-15
US8071074B2 (en) 2011-12-06
MY126490A (en) 2006-10-31
DK1119349T3 (da) 2008-10-13
PH12010000216A1 (en) 2015-07-27
CA2337422A1 (en) 2000-03-02
HUP0103894A3 (en) 2003-07-28
AU5676699A (en) 2000-03-14
AR020220A1 (es) 2002-05-02
CZ2001584A3 (cs) 2002-06-12
UA73722C2 (en) 2005-09-15
WO2000010588A3 (en) 2001-05-25
ES2310047T3 (es) 2008-12-16
CO5130028A1 (es) 2002-02-27
JP2002539072A (ja) 2002-11-19
SI1119349T1 (sl) 2008-12-31
CN1354657A (zh) 2002-06-19
EP1970058A1 (en) 2008-09-17
PT1119349E (pt) 2008-10-14
US6566324B2 (en) 2003-05-20

Similar Documents

Publication Publication Date Title
MY126490A (en) Preventing airway mucus production by administration of egf-r antagonists
BR0212586A (pt) Composição, uso de uma combinação de ipratrópio ou um sal deste e de xilometazolina ou um sal desta, e, métodos para o tratamento de uma condição selecionada ao grupo que consiste de sintomas associados com o resfriado comum e sintomas associaods com a rinite e para estabilizar uma solução aquosa de ipratrópio ou um sal deste e xilometazolina ou um sal desta
Resta et al. Estradiol-induced attenuation of pulmonary hypertension is not associated with altered eNOS expression
Brodde et al. Coexistence of beta 1-and beta 2-adrenoceptors in human right atrium. Direct identification by (+/-)-[125I] iodocyanopindolol binding.
Franks Molecular targets underlying general anaesthesia
Patel et al. Angiotensin IV receptor-mediated activation of lung endothelial NOS is associated with vasorelaxation
Goldie Endothelins in health and disease: an overview
BRPI0311812B8 (pt) antagonistas de receptor de peptídeo relacionado com o gene de calcitonina, composição farmacêutica e seu uso
Albers et al. Somatostatin receptor gene expression in neuroblastoma
BR0107371A (pt) Formulação de inìcio rápido
BR0108386C1 (pt) urato oxidase purificada (uricase), conjugado de uricase, composição farmacêutica para reduzir os nìveis de ácido úrico nos fluidos ou tecidos corporais, método para a purificação de uricase dotada de imunogenicidade reduzida
BR0010348A (pt) Uso de antagonistas seletivos de receptor <244>~ 1b~-adrenérgico para aperfeiçoamento de disfunção sexual
BR0113213A (pt) Método para diagnosticar uma doença auto-imune, anticorpo, composição de diagnóstico, e, uso do anticorpo
BR0210720A (pt) Composto e uso do mesmo
Benson et al. Mechanisms of vasodilation to PTH 1–84, PTH 1–34, and PTHrP 1–34 in rat bone resistance arteries
BR0107958A (pt) Composição farmacêutica contendo pemetrexado juntamente com l-cisteìna monotrioglicerol ou ácido tioglicólico
WO2002005842A3 (en) Preventing airway mucus production by administration of egf-r antagonists
Wu et al. EPO promotes the progression of rheumatoid arthritis by inducing desialylation via increasing the expression of neuraminidase 3
BR9711414A (pt) Processo e composições farmacêuticas para abaixamento do nìvel de ácido úrico no organismo humano e para profilaxia da gota, hiperuricemia ou doença cardìaca coronária em humanos, e, uso de um composto
Roffel et al. No evidence for a role of muscarinic M2 receptors in functional antagonism in bovine trachea
Greenberg et al. Phenytoin interacts with calcium channels in brain membrances
Chand 5-Hydroxytryptamine induces relaxation of goat pulmonary veins: evidence for the noninvolvement of M and D-tryptamine receptors
Prancan et al. Relaxation of the guinea-pig trachea induced by platelet-activating factor and by serotonin
Mathé Prostaglandins and the lung
Rong et al. Probing the salmeterol binding site on the β2-adrenergic receptor using a novel photoaffinity ligand,[125I] iodoazidosalmeterol

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O C/C 11 E 13 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2256 DE 01/04/2014.